6 results
The primary efficacy variable is the change in PV from baseline as assessed by 3 D ultrasonography after 78 weeks of double-blind treatment with OM 20-40 mg daily compared to ATE 50-100 mg daily.Secondary efficacy variables:Change from baseline PV…
This study is looking at how safe the combination of the experimental drugs dostarlimab, belrestotug and GSK6097608 is in patients with previously untreated, advanced or metastatic non-small cell lung cancer. And how well the combination works. We…
To evaluate the effect of triple-therapy wih Budesonide, Glycopyrronium and Formoterol Fumarate (PT010) versus dual therapy with Budesonide and Formoterol Fumarate on asthma exacerbations in adult and adolescent subjects with inadequately controlled…
DOSE EXPLORATION:Primary:To determine the safety and tolerability of GSK2857916 in combination with other anti-cancer treatments (in each sub-study), and to establish the recommended Phase 2 dose for each sub-study combination treatment.Secondary:…
Primary objective:To estimate the efficacy of dostarlimab in participants with Stage II/III (locally advanced) dMMR/MSI-H rectal cancer that has not been previously treatedSecondary Objectives:- To further estimate the efficacy of dostarlimab in…
Primary (PART 1A ONLY):Dose escalation: To determine the safety, tolerability, and the recommended phase 2 dose (RP2D) of GSK3745417 alone administered intravenously to participants with selected advanced/recurrent solid tumors.Secondary: (PART 1A…